Do you want to read an article? Please log in or register.
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Multiple Sclerosis
Related content
Multiple Sclerosis
Fingolimod vs dimethyl fumarate in multiple sclerosis: A real-world propensity score-matched study
Neurology.
Prosperini L, Lucchini M, Haggiag S, Bellantonio P, Bianco A, Buscarinu MC, Buttari F, Centonze D, Cortese A, De Giglio L, Fantozzi R, Ferraro E, Fornasiero A, Francia A, Galgani S, Gasperini C, Marfia GA, Millefiorini E, Nociti V, Pontecorvo S, Pozzilli C, Ruggieri S, Salvetti M, Sgarlata E, Mirabella M
doi: 10.1212/WNL.
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
Multiple Sclerosis
Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies
Eur J Neurol.
Havrdova E, Giovannoni G, Gold R, Fox RJ, Kappos L, Phillips JT, Okwuokenye M, Marantz JL
doi: 10.1111/ene.13272.
Multiple Sclerosis
Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis
J Autoimmun.
Diebold M, Sievers C, Bantug G, Sanderson N, Kappos L, Kuhle J, Lindberg RLP, Derfuss T
doi: 10.1016/j.jaut.2017.09.009.
RECOMMENDED
Multiple Sclerosis
Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study
Neurology.
Buron MD, Chalmer TA, Sellebjerg F, Frederiksen J, Góra MK, Illes Z, Kant M, Mezei Z, Petersen T, Rasmussen PV, Roshanisefat H, Hassanpour-Kalam-Roudy H, Sejbæk T, Tsakiri A, Weglewski A, Sorensen PS, Magyari M
doi: 10.1212/WNL.
Multiple Sclerosis
What's new about oral treatments in Multiple Sclerosis? Immunogenetics still under question
Pharmacol Res.
Pistono C, Osera C, Boiocchi C, Mallucci G, Cuccia M, Bergamaschi R, Pascale A
doi: 10.1016/
RECOMMENDED
EpilepsyMultiple Sclerosis
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
N Engl J Med.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J, PARADIGMS Study Group
doi: 10.1056/NEJMoa1800149.
Multiple Sclerosis
Real-World Characterization of Dimethyl Fumarate-Related Gastrointestinal Events in Multiple Sclerosis: Management Strategies to Improve Persistence on Treatment and Patient Outcomes
Neurol Ther.
Min J, Cohan S, Alvarez E, Sloane J, Phillips JT, van der Walt A, Koulinska I, Fang F, Miller C, Chan A
doi: 10.1007/
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.